Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ Dispatch Post published:April 23, 2024 Post category:Analysis/News/Pα+
MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic Therapies Post published:April 5, 2024 Post category:Analysis/Pα+
ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient” Post published:March 27, 2024 Post category:Analysis/News/Pα+
Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder Post published:March 14, 2024 Post category:Analysis/News/Pα+
Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data Post published:March 13, 2024 Post category:Analysis/News/Pα+
FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans Post published:March 7, 2024 Post category:Analysis/News/Pα+
Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice Post published:March 4, 2024 Post category:Analysis/News/Pα+
Ibogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky Post published:February 23, 2024 Post category:Analysis/News
Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 16, 2024 Post category:Analysis/Pα+
Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 14, 2024 Post category:Analysis/Pα+